Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Immuno-Oncology Congress 2021, Geneva, Switzerland, 8-11 December

26 Nov 2021

LUGANO, Switzerland – The ESMO Immuno-Oncology Congress 2021, the European platform dedicated to the development and use of immunotherapies for cancer treatment, will be held as an onsite and online congress.

The Scientific programme will provide a comprehensive overview of immunotherapy-based cancer treatment, from the basics of immunotherapies to the latest research results, and from the understanding of the different treatment options to the management of toxicities and interpretation of new data.

Programme highlights

  • New immunotherapies to improve the treatment of solid tumours: From cell-based therapies to soluble T-cell engagers and T-cell co-stimulation
  • Biomarkers for immunotherapy: The future is in the hand of tools built on combinations
  • Trained immunity as a new promising oncology target
  • Tumour mutational burden as a number to enhance prediction of outcomes in patients treated with immune checkpoint inhibitors
  • Updates and novel data in melanoma, haematological malignancies, gastrointestinal, thoracic, head and neck, breast and gynecological cancers

ESMO Immuno-Oncology 2020 and 2021 Keynote lectures

  •  “The crucial players of the immune microenvironment”, by Wolf-Hervé Fridman, winner of the ESMO Immuno-Oncology 2021 Award
  • “Checkpoint blockade therapy for melanoma: combinations to improve outcomes” by Jedd D. Wolchok, winner of the ESMO Immuno-Oncology 2020 Award

Media accreditation

ESMO welcomes media interested in reporting from the ESMO events and on cancer issues. Only through the official accreditation process with the ESMO Media Registration Form, accredited media representatives will be able to access scientific and educational sessions (in person, live streamed and on-demand), live Q&A with invited speakers, e-posters, exhibition and industry satellite symposia, post-event resources. 

Participants attending in person must follow the COVID-19 safety regulations that ESMO will apply according to the latest local authority guidelines and requirements. 

To enter the congress venue everyone will be required to show:

  • A certificate providing evidence of being fully vaccinated against COVID-19, OR
  • A certificate showing proof of recovery from COVID-19 in the last 6 months

Additionally, for all it is requested:

  • Proof of negative PCR test or rapid antigen test not older than 48 hours.

Further information

ESMO Press Office

Notes to Editors

Please make sure to use the official name of the meeting in your reports: ESMO Immuno-Oncology Congress 2021

Official Congress hashtag: #ESMOImmuno21

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.